Small Molecule Expertise

Small molecule drugs are used to treat a wide variety of diseases, including cancer, infectious diseases, cardiovascular diseases, and neurological disorders. Small molecule drugs have played a major role in the development of modern medicine. They have saved millions of lives and improved the quality of life for millions more people.


Accelerate Your Small Molecule Drug Development With Our Preclinical Expertise

Are you developing small molecule drugs? If so, you know that the preclinical phase of drug development is critical to the success of your program. Our contract research organization (CRO) has a proven track record of helping clients accelerate their preclinical work and bring their small molecule drugs to market quickly and efficiently.

We offer a comprehensive range of preclinical services, including:

    • Target validation and identification
    • Assay development and screening
    • Lead optimization
    • Preclinical toxicology
    • Biodistribution and pharmacokinetics
    • Drug metabolism and pharmacokinetics (DMPK)
    • Safety pharmacology

Our team of experienced scientists and technicians has a deep understanding of small molecule drugs and the preclinical drug development process. We are committed to providing our clients with the highest quality services and support to help them achieve their drug development goals.

Small molecules: Defined as organic compounds with low molecular weight, small molecule drugs have been the mainstay of the pharmaceutical industry for almost a century. The rapid advancement of high-throughput screening, biopharmaceutical research, and technology opens up possibilities for innovative and creative new approaches to developing small molecule drugs.


ProTide technology approach has been successfully applied to a vast number of nucleoside analogs with anticancer and antiviral activity which have led to several FDA-approved drugs and preclinical candidates. ProTide drugs are designed to deliver nucleotides and nucleoside analogs into cells more efficiently than traditional drugs.

Learn more about our preclinical development services for ProTides.


Nucleoside drugs mimic endogenous nucleosides, exploiting cellular metabolism and becoming incorporated into both DNA and RNA. This property makes nucleoside analogs effective at inhibiting viral replication and stopping cancer cell proliferation. Currently, there are more than twenty different nucleoside analogs available in the clinic to treat viral infections and cancer.

Learn more about our preclinical development services for Nucleosides.

Antibody Drug Conjugates

Antibody drug conjugates (ADCs) are a type of targeted cancer therapy that combines the power of antibodies with the potency of chemotherapy drugs. When an ADC is administered to a patient, the antibody binds to the tumor cell antigen. The linker then releases the chemotherapy drug into the tumor cell, where it kills the cancer cell.

Learn more about our preclinical development services for ADCs.


PROTACs, or proteolysis targeting chimeras, are a new class of drugs that hijack the cell’s own protein degradation machinery to target and destroy specific unwanted proteins. PROTACs work by binding to two targets: the unwanted protein and an E3 ubiquitin ligase.

Learn more about our preclinical development services for PROTACs.

Our Experts

Corinne E.
Augelli-Szafran, Ph.D.

Vice President of Scientific Platforms

Rebecca Boohaker, Ph.D.

Director of Oncology

Omar Moukha-Chafiq, Ph.D.

Director of Chemistry

Partner With Us

We have commercial, government, and industry partnership opportunities. Our work includes licensing patents, co-investing in furthering intellectual property, collaborating to create new intellectual property, and leveraging research to drive biotechnology product development.